SCHEMBL4428869

SCHEMBL4428869

CCOC(=O)c1ccc(-c2ccc(F)cc2F)nc1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.57
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
MAPT P10636 1/20 0.52
CASP3 P42574 2/20 0.51
SENP8 Q96LD8 2/20 0.51
SENP7 Q9BQF6 2/20 0.51
SENP6 Q9GZR1 2/20 0.51
ATM Q13315 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
KDM4E B2RXH2 5/20 0.46
MDM2 Q00987 1/20 0.46
ALDH1A1 P00352 5/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
ALPL P05186 1/20 0.44
KMO O15229 1/20 0.44
HPGD P15428 4/20 0.43
HSD17B10 Q99714 2/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4434614 0.82 KMO (0.56) NPC1RAB9AMAPTCASP3SENP8
SCHEMBL4386607 0.81 RAB9A (0.74) TSHRNPC1RAB9AMAPTCASP3
SCHEMBL10026437 0.80 TSHR (0.51) TSHRNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL4426818 0.80 RAB9A (0.60) TSHRNPC1RAB9AMAPTCASP3
SCHEMBL4422146 0.80 MDM2 (0.48) TSHRNPC1RAB9AMAPTCASP3
SCHEMBL367075 0.79 TSHR (0.57) TSHRNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL4433477 0.78 RAB9A (0.65) TSHRNPC1RAB9AMAPTCASP3
SCHEMBL1608842 0.78 TSHR (0.49) TSHRNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL25414490 0.76 MAPT (0.51) TSHRNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL25415867 0.76 MAPT (0.66) TSHRNPC1RAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538121-B2 Vanilloid receptor modulators GLAXO GROUP LIMITED (GB) 2009-05-26 US disclosed
EP-2033953-A1 Vanilloid receptor modulators Glaxo Group Limited (GB) 2009-03-11 EP disclosed
US-20060142333-A1 Vanilloid receptor modulators MACDONALD GREGOR J 2006-06-29 US disclosed
EP-1480954-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2004-12-01 EP disclosed
WO-2003068749-A1 VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142333-A1 Vanilloid receptor modulators TRPV1, NPSR1, TRPV3 TSHR 395/4885NPC1 784/4885RAB9A 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.